Johnson & Johnson’s vaccine was originally designed as a single-dose vaccine.
Posted
Update
Reading time : 1 min.
The European Medicines Agency (EMA) announced Monday, November 22 that it was in the process of evaluating a request from the Johnson & Johnson laboratory. It involves injecting a booster dose with the vaccine he designed against Covid-19 to people aged 18 or over in the EU. “The EMA’s Committee for Medicinal Products for Human Use (CHMP) will carry out an accelerated assessment of the data submitted by the company that markets the vaccine”, said the European regulator, adding that a result was “expected in the next few weeks”.
The vaccine Johnson & johnson was originally designed as a single dose vaccine. But with a second dose injected about two months (56 days) after the first, the antibody levels observed are multiplied. “by four to six”, reported the US pharmaceutical company in September. The vaccine’s efficacy against symptomatic cases of the disease at least 14 days after the injection of this booster dose was then 75%, and 100% against severe cases, according to data from a clinical trial conducted in several countries, among people aged 18 and over.